Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $29.73M fell 35.7% year over year, ahead of the -39.9% change in trailing-twelve-month operating expenses. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.

Context

  • Operating expenses amounted to 207.0% of revenue in FY2025, up 37.9 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -35.7% holds above the trailing-twelve-month pace of -39.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29.73M-13.5% QoQ
Last fiscal yearDec 2025
$139.15M-40.5% YoY
LTMMar 2026
$130.57M-39.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.7%——
1 year-40.5%——
3-year CAGR-10.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
139.15M USD
Year-over-year change
-40.5%
4-year CAGR
-10.3%

Operating Expenses vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.9% is the 9th highest of 10, against a peer median of -1.4%.
  • Operating expenses amounts to 287.9% of revenue for ARCT, versus a peer median of 265.5%.
ARCT Competitors
Operating Expenses for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$641.93M USD+299.5%+48.0%980.1%
NVAXNovavax, Inc.LTM Mar 2026$571.48M USD-16.7%-28.6%95.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$213.72M USD-20.2%-1.0%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$149.1M USD+7.6%+38.4%—
VALNValneva SELTM Mar 2026€145.42M EUR-1.4%-0.3%93.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$130.57M USD-39.9%-10.4%287.9%
SLNSilence Therapeutics plcLTM Mar 2026$87.2M USD—+16.9%9463.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$81.48M USD-22.1%-32.1%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€58.51M EUR+12.1%-7.3%435.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026$53.82M USD+43.6%+32.6%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$36.74M USD-54.2%-26.9%19.2%
Peer median (excluding ARCT) —-1.4%-0.6%265.5%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.